Nature Communications (Nov 2022)
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer
- Nan Niu,
- Fang Qiu,
- Qianshi Xu,
- Guijin He,
- Xi Gu,
- Wenbin Guo,
- Dianlong Zhang,
- Zhigao Li,
- Yi Zhao,
- Yong Li,
- Ke Li,
- Hao Zhang,
- Peili Zhang,
- Yuanxi Huang,
- Gangling Zhang,
- Hongbin Han,
- Zhengang Cai,
- Pengfei Li,
- Hong Xu,
- Guanglei Chen,
- Jinqi Xue,
- Xiaofan Jiang,
- Alireza Hamidian Jahromi,
- Jinshi Li,
- Yu Zhao,
- Eduardo de Faria Castro Fleury,
- Shiwen Huo,
- Huajun Li,
- Guy Jerusalem,
- Domenico Tripodi,
- Tong Liu,
- Xinyu Zheng,
- Caigang Liu
Affiliations
- Nan Niu
- Department of Oncology, Shengjing Hospital of China Medical University
- Fang Qiu
- Department of Oncology, Shengjing Hospital of China Medical University
- Qianshi Xu
- Department of Oncology, Shengjing Hospital of China Medical University
- Guijin He
- Department of Oncology, Shengjing Hospital of China Medical University
- Xi Gu
- Department of Oncology, Shengjing Hospital of China Medical University
- Wenbin Guo
- Department of Breast Surgery, Dalian Municipal Central Hospital, Affiliated Hospital of Dalian Medical University
- Dianlong Zhang
- Department of Breast Surgery, Affiliated Zhongshan Hospital of Dalian University
- Zhigao Li
- Department of Breast Surgery, Cancer Hospital of Harbin Medical University
- Yi Zhao
- Department of Oncology, Shengjing Hospital of China Medical University
- Yong Li
- Department of Breast Surgery, Benxi Central Hospital, The Fifth Affiliated Hospital of China Medical University
- Ke Li
- Department of Breast Surgery, Anshan Cancer Hospital
- Hao Zhang
- Department of Breast Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
- Peili Zhang
- Department of Breast Surgery, Baotou Cancer Hospital
- Yuanxi Huang
- Department of Breast Surgery, Cancer Hospital of Harbin Medical University
- Gangling Zhang
- Department of Breast Surgery, Baotou Cancer Hospital
- Hongbin Han
- Department of Breast Surgery, Liaohe Oilfield General Hospital, Affiliated Hospital of China Medical University
- Zhengang Cai
- Department of Breast Surgery, the First Affiliated Hospital of Dalian Medical University
- Pengfei Li
- Department of Thoracic and Breast Surgery, Yan’an People’s Hospital
- Hong Xu
- Department of Breast Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
- Guanglei Chen
- Department of Oncology, Shengjing Hospital of China Medical University
- Jinqi Xue
- Department of Oncology, Shengjing Hospital of China Medical University
- Xiaofan Jiang
- Department of Oncology, Shengjing Hospital of China Medical University
- Alireza Hamidian Jahromi
- Division of Plastic and Reconstructive Surgery, Temple University Medical Center
- Jinshi Li
- Department of Anesthesiology, the First Affiliated Hospital of China Medical University
- Yu Zhao
- Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine
- Eduardo de Faria Castro Fleury
- Instituto Brasileiro de Controle do Câncer Oncologia (IBCC Oncologia)
- Shiwen Huo
- Jiangsu Hengrui Pharmaceuticals
- Huajun Li
- Jiangsu Hengrui Pharmaceuticals
- Guy Jerusalem
- Medical Oncology Department, CHU Liège and Liège University
- Domenico Tripodi
- Department of Surgical Sciences, Sapienza University of Rome
- Tong Liu
- Department of Breast Surgery, Cancer Hospital of Harbin Medical University
- Xinyu Zheng
- Department of Breast Surgery, The First Affiliated Hospital of China Medical University
- Caigang Liu
- Department of Oncology, Shengjing Hospital of China Medical University
- DOI
- https://doi.org/10.1038/s41467-022-34838-w
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 9
Abstract
Neoadjuvant therapy is recommended for patients with locally advanced breast cancer. Here the authors report the results of a phase 2 clinical trial of oral neoadjuvant therapy with pyrotinib (pan-HER tyrosine kinase inhibitor), letrozole (aromatase inhibitor) and dalpiciclib (CDK4/6 inhibitor) in patients with treatment-naïve and stage II-III triple positive breast cancer.
